Cargando…
Sex differences in systemic lupus erythematosus (SLE): an inception cohort of the Chinese SLE Treatment and Research Group (CSTAR) registry XVII
BACKGROUND: The onset and clinical presentation of systemic lupus erythematosus (SLE) are sex-related. Few studies have investigated the distinctions in clinical characteristics and treatment preferences in male and female SLE patients in the initial cohort. This study aimed to improve the understan...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771188/ https://www.ncbi.nlm.nih.gov/pubmed/36525605 http://dx.doi.org/10.1097/CM9.0000000000002360 |
_version_ | 1784854766552088576 |
---|---|
author | Gui, Yinli Bai, Wei Xu, Jian Duan, Xinwang Zhan, Feng Zhao, Chen Jiang, Zhenyu Li, Zhijun Wu, Lijun Liu, Shengyun Yang, Min Wei, Wei Wang, Ziqian Zhao, Jiuliang Wang, Qian Leng, Xiaomei Tian, Xinping Li, Mengtao Zhao, Yan Zeng, Xiaofeng |
author_facet | Gui, Yinli Bai, Wei Xu, Jian Duan, Xinwang Zhan, Feng Zhao, Chen Jiang, Zhenyu Li, Zhijun Wu, Lijun Liu, Shengyun Yang, Min Wei, Wei Wang, Ziqian Zhao, Jiuliang Wang, Qian Leng, Xiaomei Tian, Xinping Li, Mengtao Zhao, Yan Zeng, Xiaofeng |
author_sort | Gui, Yinli |
collection | PubMed |
description | BACKGROUND: The onset and clinical presentation of systemic lupus erythematosus (SLE) are sex-related. Few studies have investigated the distinctions in clinical characteristics and treatment preferences in male and female SLE patients in the initial cohort. This study aimed to improve the understanding of Chinese SLE patients by characterizing the different sexes of SLE patients in the inception cohort. METHODS: Based on the initial patient cohort established by the Chinese SLE Treatment and Research Group, a total of 8713 patients (795 men and 7918 women) with newly diagnosed SLE were enrolled between April 2009 and March 2021. Of these, 2900 patients (347 men and 2553 women) were eligible for lupus nephritis (LN). A cross-sectional analysis of the baseline demographic characteristics, clinical manifestations, laboratory parameters, organ damage, initial treatment regimens, and renal pathology classification was performed according to sex. RESULTS: In the SLE group, as compared to female patients, male patients had a later age of onset (male vs. female: 37.0 ± 15.8 years vs. 35.1 ± 13.7 years, P = 0.006) and a higher SLE International Collaborative Clinic/American College of Rheumatology damage index score (male vs. female: 0.47 ± 1.13 vs. 0.34 ± 0.81, P = 0.015), LN (male vs. female: 43.6% vs. 32.2%, P < 0.001), fever (male vs. female: 18.0% vs. 14.6%, P = 0.010), thrombocytopenia (male vs. female: 21.4% vs. 18.5%, P = 0.050), serositis (male vs. female: 14.7% vs. 11.7%, P = 0.013), renal damage (male vs. female: 11.1% vs. 7.4%, P < 0.001), and treatment with cyclophosphamide (CYC) (P < 0.001). The frequency of leukopenia (male vs. female: 20.5% vs. 25.4%, P = 0.002) and arthritis (male vs. female: 22.0% vs. 29.9%, P < 0.001) was less in male patients with SLE. In LN, no differences were observed in disease duration, SLE Disease Activity Index score, renal biopsy pathological typing, or 24-h urine protein quantification among the sexes. In comparisons with female patients with LN, male patients had later onset ages (P = 0.026), high serum creatinine (P < 0.001), higher end-stage renal failure rates (P = 0.002), musculoskeletal damage (P = 0.023), cardiovascular impairment (P = 0.009), and CYC use (P = 0.001); while leukopenia (P = 0.017), arthritis (P = 0.014), and mycophenolate usage (P = 0.013) rates were lower. CONCLUSIONS: Male SLE patients had more severe organ damage and a higher LN incidence compared with female SLE patients; therefore, they may require more aggressive initial treatment compared to female patients. |
format | Online Article Text |
id | pubmed-9771188 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-97711882022-12-22 Sex differences in systemic lupus erythematosus (SLE): an inception cohort of the Chinese SLE Treatment and Research Group (CSTAR) registry XVII Gui, Yinli Bai, Wei Xu, Jian Duan, Xinwang Zhan, Feng Zhao, Chen Jiang, Zhenyu Li, Zhijun Wu, Lijun Liu, Shengyun Yang, Min Wei, Wei Wang, Ziqian Zhao, Jiuliang Wang, Qian Leng, Xiaomei Tian, Xinping Li, Mengtao Zhao, Yan Zeng, Xiaofeng Chin Med J (Engl) Original Articles BACKGROUND: The onset and clinical presentation of systemic lupus erythematosus (SLE) are sex-related. Few studies have investigated the distinctions in clinical characteristics and treatment preferences in male and female SLE patients in the initial cohort. This study aimed to improve the understanding of Chinese SLE patients by characterizing the different sexes of SLE patients in the inception cohort. METHODS: Based on the initial patient cohort established by the Chinese SLE Treatment and Research Group, a total of 8713 patients (795 men and 7918 women) with newly diagnosed SLE were enrolled between April 2009 and March 2021. Of these, 2900 patients (347 men and 2553 women) were eligible for lupus nephritis (LN). A cross-sectional analysis of the baseline demographic characteristics, clinical manifestations, laboratory parameters, organ damage, initial treatment regimens, and renal pathology classification was performed according to sex. RESULTS: In the SLE group, as compared to female patients, male patients had a later age of onset (male vs. female: 37.0 ± 15.8 years vs. 35.1 ± 13.7 years, P = 0.006) and a higher SLE International Collaborative Clinic/American College of Rheumatology damage index score (male vs. female: 0.47 ± 1.13 vs. 0.34 ± 0.81, P = 0.015), LN (male vs. female: 43.6% vs. 32.2%, P < 0.001), fever (male vs. female: 18.0% vs. 14.6%, P = 0.010), thrombocytopenia (male vs. female: 21.4% vs. 18.5%, P = 0.050), serositis (male vs. female: 14.7% vs. 11.7%, P = 0.013), renal damage (male vs. female: 11.1% vs. 7.4%, P < 0.001), and treatment with cyclophosphamide (CYC) (P < 0.001). The frequency of leukopenia (male vs. female: 20.5% vs. 25.4%, P = 0.002) and arthritis (male vs. female: 22.0% vs. 29.9%, P < 0.001) was less in male patients with SLE. In LN, no differences were observed in disease duration, SLE Disease Activity Index score, renal biopsy pathological typing, or 24-h urine protein quantification among the sexes. In comparisons with female patients with LN, male patients had later onset ages (P = 0.026), high serum creatinine (P < 0.001), higher end-stage renal failure rates (P = 0.002), musculoskeletal damage (P = 0.023), cardiovascular impairment (P = 0.009), and CYC use (P = 0.001); while leukopenia (P = 0.017), arthritis (P = 0.014), and mycophenolate usage (P = 0.013) rates were lower. CONCLUSIONS: Male SLE patients had more severe organ damage and a higher LN incidence compared with female SLE patients; therefore, they may require more aggressive initial treatment compared to female patients. Lippincott Williams & Wilkins 2022-09-20 2022-10-20 /pmc/articles/PMC9771188/ /pubmed/36525605 http://dx.doi.org/10.1097/CM9.0000000000002360 Text en Copyright © 2022 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Original Articles Gui, Yinli Bai, Wei Xu, Jian Duan, Xinwang Zhan, Feng Zhao, Chen Jiang, Zhenyu Li, Zhijun Wu, Lijun Liu, Shengyun Yang, Min Wei, Wei Wang, Ziqian Zhao, Jiuliang Wang, Qian Leng, Xiaomei Tian, Xinping Li, Mengtao Zhao, Yan Zeng, Xiaofeng Sex differences in systemic lupus erythematosus (SLE): an inception cohort of the Chinese SLE Treatment and Research Group (CSTAR) registry XVII |
title | Sex differences in systemic lupus erythematosus (SLE): an inception cohort of the Chinese SLE Treatment and Research Group (CSTAR) registry XVII |
title_full | Sex differences in systemic lupus erythematosus (SLE): an inception cohort of the Chinese SLE Treatment and Research Group (CSTAR) registry XVII |
title_fullStr | Sex differences in systemic lupus erythematosus (SLE): an inception cohort of the Chinese SLE Treatment and Research Group (CSTAR) registry XVII |
title_full_unstemmed | Sex differences in systemic lupus erythematosus (SLE): an inception cohort of the Chinese SLE Treatment and Research Group (CSTAR) registry XVII |
title_short | Sex differences in systemic lupus erythematosus (SLE): an inception cohort of the Chinese SLE Treatment and Research Group (CSTAR) registry XVII |
title_sort | sex differences in systemic lupus erythematosus (sle): an inception cohort of the chinese sle treatment and research group (cstar) registry xvii |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771188/ https://www.ncbi.nlm.nih.gov/pubmed/36525605 http://dx.doi.org/10.1097/CM9.0000000000002360 |
work_keys_str_mv | AT guiyinli sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii AT baiwei sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii AT xujian sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii AT duanxinwang sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii AT zhanfeng sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii AT zhaochen sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii AT jiangzhenyu sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii AT lizhijun sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii AT wulijun sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii AT liushengyun sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii AT yangmin sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii AT weiwei sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii AT wangziqian sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii AT zhaojiuliang sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii AT wangqian sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii AT lengxiaomei sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii AT tianxinping sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii AT limengtao sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii AT zhaoyan sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii AT zengxiaofeng sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii |